- Gene editor Scribe starts second-half IPO spree with $129M listingA nine-year-old biotech co-founded by CRISPR pioneer Jennifer Doudna is kicking off a run of biotech IPOs set for this year's second half. Scribe Therapeutics priced its $128.7 millionEndpoints · 1d ago↗ source
- This Week at FDA: Diamantas touts onshoring efforts, grants for DHTs, and more<p>Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug, and medical device regulation, and what we’re reading from around the web. This…raps · 1d ago↗ source
- FDA advisory committee backs two more peptides, rejects one for compounding list<p>By the end of a two-day meeting that concluded Friday afternoon, an advisory committee to the US Food and Drug Administration (FDA) voted in favor of adding six of the seven peptides it was task…